These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 23436821)

  • 1. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.
    Vermeer M; Kuper HH; Moens HJ; Drossaers-Bakker KW; van der Bijl AE; van Riel PL; van de Laar MA
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1219-26. PubMed ID: 23436821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.
    Schipper LG; Vermeer M; Kuper HH; Hoekstra MO; Haagsma CJ; Den Broeder AA; van Riel P; Fransen J; van de Laar MA
    Ann Rheum Dis; 2012 Jun; 71(6):845-50. PubMed ID: 22210852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
    Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
    Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
    Ramiro S; Landewé RB; van der Heijde D; Sepriano A; FitzGerald O; Ostergaard M; Homik J; Elkayam O; Thorne JC; Larche M; Ferraccioli G; Backhaus M; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel AG; Allaart CF; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Dadashova R; Hutchings E; Paschke J; Maksymowych WP
    Ann Rheum Dis; 2020 Apr; 79(4):453-459. PubMed ID: 32094157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
    Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?
    Konijn NPC; van Tuyl LHD; Boers M; den Uyl D; Ter Wee MM; Kerstens P; Voskuyl AE; van Schaardenburg D; Nurmohamed MT; Lems WF
    Arthritis Care Res (Hoboken); 2017 Jul; 69(7):989-996. PubMed ID: 27696732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
    Wabe NT; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee AT; Spargo LD; Metcalf RG; Hall C; Proudman SM; Wiese MD
    J Rheumatol; 2016 Sep; 43(9):1643-9. PubMed ID: 27422892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.
    Versteeg GA; Steunebrink LMM; Vonkeman HE; Ten Klooster PM; van der Bijl AE; van de Laar MAFJ
    Clin Rheumatol; 2018 May; 37(5):1189-1197. PubMed ID: 29388086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.
    Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE;
    Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome.
    van Tuyl LH; Britsemmer K; Wells GA; Smolen JS; Zhang B; Funovits J; van Schaardenburg D; Felson D; Boers M
    Ann Rheum Dis; 2012 Jan; 71(1):33-7. PubMed ID: 21953347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
    Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Christensen R; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Nielsen SM; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
    JAMA; 2019 Feb; 321(5):461-472. PubMed ID: 30721294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network.
    Nikiphorou E; Norton SJ; Carpenter L; Walsh DA; Creamer P; Dixey J; Young A; Kiely PDW;
    Rheumatology (Oxford); 2020 Jun; 59(6):1272-1280. PubMed ID: 31580448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.
    Vermeer M; Kievit W; Kuper HH; Braakman-Jansen LM; Bernelot Moens HJ; Zijlstra TR; den Broeder AA; van Riel PL; Fransen J; van de Laar MA
    BMC Musculoskelet Disord; 2013 Dec; 14():350. PubMed ID: 24330489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes.
    Ruyssen-Witrand A; Guernec G; Nigon D; Tobon G; Jamard B; Rat AC; Vittecoq O; Cantagrel A; Constantin A
    Ann Rheum Dis; 2015 Sep; 74(9):1676-83. PubMed ID: 24794151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes.
    Paulshus Sundlisæter N; Aga AB; Olsen IC; Hammer HB; Uhlig T; van der Heijde D; Kvien TK; Lillegraven S; Haavardsholm EA;
    Ann Rheum Dis; 2018 Oct; 77(10):1421-1425. PubMed ID: 29934373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
    Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
    Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis.
    Sakellariou G; Scirè CA; Verstappen SM; Montecucco C; Caporali R
    Ann Rheum Dis; 2013 Feb; 72(2):245-9. PubMed ID: 23060009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.